Eli Lilly is acquiring all rights to a therapeutic migraine antibody that it discovered and then licensed to new company Arteaus Therapeutics for development in 2011.
Arteaus was formed with an $18m investment from Atlas Venture and OrbiMed solely for the development of the calcitonin gene-related...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
